Key result
Risk-stratified therapy improves acute PE outcomes by assessing early mortality risk and RV function.
Why the study?
Therapeutic management of acute pulmonary embolism has evolved toward a risk-stratified approach, prompting a review of current evidence on anticoagulation, thrombolysis, and catheter-directed thrombectomy.
Therapeutic management of acute pulmonary embolism has evolved to a risk-stratified approach based on early mortality risk and right ventricular function.
Should integrate early mortality risk and RV function to guide acute PE therapy; reinforces guidelines endorsing risk-adapted management.
Acute pulmonary embolism (PE) represents a major clinical challenge, characterised by a wide spectrum of phenotypic presentations ranging from asymptomatic disease to cardiovascular collapse. Therapeutic management has evolved from a dichotomous paradigm (anticoagulation vs thrombolysis) to a risk-stratified approach based on early mortality risk and right ventricular (RV) function. This article critically reviews current evidence regarding parenteral and oral anticoagulation, systemic thrombolysis, and emerging catheter-directed thrombectomy techniques, in light of the 2019 European Society of Cardiology (ESC) guidelines and recent clinical trials.
No takes yet. Share an insight, caveat, or question.
Manzi et al. (2026) studied this question. A risk-stratified therapeutic approach improves outcomes in acute pulmonary embolism by considering early mortality risk and right ventricular function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: